Article
Chemistry, Multidisciplinary
Chaebin Lee, Xiangji Liu, Weizhong Zhang, Michael A. Duncan, Fangchao Jiang, Christine Kim, Xuefeng Yan, Yong Teng, Hui Wang, Wen Jiang, Zibo Li, Jin Xie
Summary: Gadolinium-intercalated carbon dots (Gd@Cdots) serve as a safe and efficient radiosensitizer, significantly enhancing cellular damage under X-ray irradiation without causing detectable toxicity. There is great potential for Gd@Cdots as a novel type of radiosensitizer for improving tumor suppression and animal survival in cancer radiotherapy.
Editorial Material
Biochemistry & Molecular Biology
Joshua R. Veatch, Sylvain Simon, Stanley R. Riddell
Summary: Preliminary results from a phase 1 trial suggest promising anti-tumor activity of tumor-infiltrating-lymphocyte therapy in patients with advanced non-small-cell lung cancer.
Review
Oncology
Qianqian Guo, Liwei Liu, Zelong Chen, Yannan Fan, Yang Zhou, Ziqiao Yuan, Wenzhou Zhang
Summary: Despite advancements in diagnosis and treatment, lung cancer mortality remains high. This review provides an overview of current diagnostic methods and therapies for non-small cell lung cancer, serving as a guide for clinicians.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Roberto Ferrara, Marie Naigeon, Edouard Auclin, Boris Duchemann, Lydie Cassard, Jean-Mehdi Jouniaux, Lisa Boselli, Jonathan Grivel, Aude Desnoyer, Laura Mezquita, Matthieu Texier, Caroline Caramella, Lizza Hendriks, David Planchard, Jordi Remon, Sabina Sangaletti, Claudia Proto, Marina C. Garassino, Jean-Charles Soria, Aurelien Marabelle, Anne-Laure Voisin, Siham Farhane, Benjamin Besse, Nathalie Chaput
Summary: T-cell immunosenescence is observed in up to 28% of patients with aNSCLC, correlating with lack of benefit from ICI treatment but not from PCT.
CLINICAL CANCER RESEARCH
(2021)
Review
Oncology
Alisa N. Blumenthaler, Mara B. Antonoff
Summary: Around half of NSCLC patients have metastatic disease at diagnosis, some with limited metastatic sites termed oligometastasis. Aggressive treatment of oligometastasis has shown improved survival rates, but the lack of a universal definition hinders comparison between studies.
Article
Oncology
Jung-hoon Lee, Ashish Saxena, Giuseppe Giaccone
Summary: Small cell lung cancer (SCLC) is a difficult-to-treat cancer that requires novel therapeutics, preclinical models, and understanding of its resistance mechanisms. Recent advancements have led to the development of new treatments, including molecular subcategorization, immunotherapy, targeted therapy, cellular therapy, and radiation therapy.
SEMINARS IN CANCER BIOLOGY
(2023)
Article
Medicine, General & Internal
Charles M. Rudin, Elisabeth Brambilla, Corinne Faivre-Finn, Julien Sage
Summary: Small-cell lung cancer is a type of lung cancer characterized by high proliferative rate, early metastasis, and poor prognosis, strongly associated with tobacco carcinogens. Most patients are diagnosed with metastatic disease, with only a small fraction having potentially curative earlier-stage disease. Genomic profiling reveals extensive chromosomal rearrangements and high mutation burden in SCLC, often involving inactivation of TP53 and RB1 tumor suppressor genes.
NATURE REVIEWS DISEASE PRIMERS
(2021)
Article
Multidisciplinary Sciences
Karolina Hanna Prazanowska, Su Bin Lim
Summary: As the importance of single-cell RNA sequencing (scRNA-seq) in studying cellular heterogeneity grows, the number of available scRNA-seq datasets has also increased rapidly. However, reusing such data is often difficult due to small cohort size, limited cell types, and insufficient information on cell type classification. Here, we present a large integrated scRNA-seq dataset containing 224,611 cells from human primary non-small cell lung cancer (NSCLC) tumors. We preprocess and integrate seven independent scRNA-seq datasets using an anchor-based approach, with validation using two additional datasets. This integrated data serves as a valuable resource for studying NSCLC transcriptome at the single cell level.
Review
Biochemistry & Molecular Biology
Min Yuan, Yu Zhao, Hendrik-Tobias Arkenau, Tongnei Lao, Li Chu, Qing Xu
Summary: Small-cell lung cancer (SCLC) is a subtype of lung cancer characterized by high proliferation, early metastasis, and poor prognosis. Recent studies have identified extensive chromosomal rearrangements, high mutation burden, and loss-of-function mutations in tumor suppressor genes in SCLC. There are currently six potential treatable signaling pathways in SCLC. However, their role in SCLC tumor biology and cancer growth promotion is not well understood. Further research is needed to optimize drug targets, improve drug pharmacology, and identify potential biomarkers for novel therapies in SCLC.
SIGNAL TRANSDUCTION AND TARGETED THERAPY
(2022)
Article
Multidisciplinary Sciences
Tzu-Hsuan Chiu, Pi-Hung Tung, Chi-Hsien Huang, Jia-Shiuan Ju, Allen Chung-Cheng Huang, Chin-Chou Wang, Ho-Wen Ko, Ping-Chih Hsu, Yueh-Fu Fang, Yi-Ke Guo, Chih-Hsi Scott Kuo, Cheng-Ta Yang
Summary: This study compared the efficacy of EGFR-TKI monotherapy and EGFR-TKI plus bevacizumab in real-world non-small cell lung cancer patients with EGFR mutation. The results showed that EGFR-TKI plus bevacizumab significantly improved overall survival and reduced the risk of death compared to EGFR-TKI monotherapy.
SCIENTIFIC REPORTS
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Florian Amstutz, Silvia Fabiano, Louise Marc, Damien Charles Weber, Antony John Lomax, Jan Unkelbach, Ye Zhang
Summary: Optimally combined proton-photon plans have been shown to improve treatment plan quality compared to IMRT alone, potentially reducing the risk of toxicity while also allowing for increased accessibility to proton therapy for NSCLC patients.
Review
Immunology
Ding-Yu Rao, De-Fa Huang, Mao-Yan Si, Hua Lu, Zhi-Xian Tang, Zu-Xiong Zhang
Summary: As an important mediator of information transfer between cells, exosomes play a unique role in regulating tumor growth, supporting vascular proliferation, tumor invasion, and metastasis. Exosomes can be used as a potential tool for non-invasive liquid biopsy due to their presence in various body fluids. This study reviews the role of exosomes in liquid biopsy, tumor microenvironment formation, and epithelial-mesenchymal transition in non-small cell lung cancer (NSCLC). It also discusses the occurrence of EGFR+ exosomes and the role of exosomes and their contents in non-invasive detection and potential therapeutic targets in EGFR-mutated lung cancer.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Oncology
Elena Corral de la Fuente, Maria Eugenia Olmedo Garcia, Ana Gomez Rueda, Yolanda Lage, Pilar Garrido
Summary: KRAS is the most frequently altered oncogene in NSCLC, and its mutant tumors have distinct biology and response to treatment, which makes developing effective drugs challenging. The recent discovery of a new pocket in KRAS G12C has led to the development of inhibitors as a new treatment option. However, resistance to targeted KRAS G12C inhibitors is also a concern, and research is ongoing to understand the mechanisms and find suitable drugs. Co-mutations and combination therapy are also areas of interest.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Yu-Ra Choi, Eun Hye Kang, Sunshin Kim, Seog-Yun Park, Ji-Youn Han, Youngjoo Lee
Summary: This study evaluated the efficacy of single MET inhibition in EGFR-mutant and MET-amplified lung cancer and found that it produced a short-lived response. Further research on novel combination therapy schedules is needed to achieve long-lasting efficacy with less toxicity.
BRITISH JOURNAL OF CANCER
(2023)
Review
Oncology
Katie Jasper, Brendon Stiles, Fiona McDonald, David A. Palma
Summary: This review summarizes the benefits of local ablative therapies in patients with oligometastatic disease in non-small-cell lung cancer and discusses a modern framework for treatment management.
JOURNAL OF CLINICAL ONCOLOGY
(2022)